IPO Cue Health

Cue Health Inc. developed a platform to enable fast and lab-quality diagnostics by anyone, anywhere. Users get the results delivered digitally to their mobile device or website account in about 20 minutes. They can also view the analysis details and get professional advice. Medium risk. Expected return – up to 80% per year.

Cue Health’s flagship product is a COVID-19 Test Kit, which was the first diagnostic test to become authorized by the FDA, for at-home use. The company has five additional Test Kits in late-stage technical development (influenza A/B, respiratory syncytial virus, fertility, pregnancy and inflammation) for which it expects to begin submitting for FDA authorization in the second half of 2022.

In 2020, the National Basketball Association used the company's test kits to prevent the spread of COVID-19 among team members. Cue Health serves 49 organizations, including the U.S. Department of Defense and the U.S. Department of Health and Human Services.

Cue Health is a beneficiary of the pandemic. Vaccination blunted the virus but didn’t defeat it completely, and the company's tests are experiencing high demand. Cue Health's revenues are up nearly 4,000% for the first half of 2021 compared to the same period in 2020.

Cue Health plans to raise $210 million through an initial public offering and sell 12.5 million shares priced between $15 and $17. Investors include ACME Capital, Leonardo DiCaprio, and Johnson & Johnson Innovation. The company boasts robust financial performance and operates in a fast-growing market. We expect a successful public offering for the company. Cue Health's value after the IPO could reach $4-5 billion.

You can apply for the investment today until 20:00 UTC+3.